Synchron Unveils OpenAI-Powered BCI Chat Feature for Interaction

Synchron announced the integration of OpenAI's generative AI into its brain-computer interface (BCI) platform. The New York-based company, known for its innovative BCI technology, has introduced a new chat feature powered by the AI maker behind ChatGPT.

BCI Technology Explained

Synchron's BCI technology is designed to decipher the neural code of the brain, aiming to restore motor intent for controlling digital devices. The system is delivered through an endovascular approach, with the implant positioned on the surface of the motor cortex via the jugular vein. This method is unique in that it captures signals from blood vessels, transmitting motor intent wirelessly out of the brain. This technology has the potential to enable severely paralyzed individuals to control personal devices hands-free using point-and-click.

Enhancing Capabilities with Generative AI

The integration of generative AI further enhances the platform's capabilities. According to Synchron, this advancement allows users with severe paralysis who have lost upper limb mobility to interact with the digital world using thought alone. The BCI chat feature is designed for simplicity, generating automated prompts for texting and chatting based on contextual inputs, including the user's emotions. Importantly, Synchron emphasizes that it does not share the BCI user's brain data with OpenAI.

Benefits of OpenAI’s Multimodal GPT

OpenAI’s multimodal GPT can generate content across text and audio, facilitating more natural, real-time human-AI interactions. When combined with BCI, it enables more efficient texting, faster response times, and natural conversation speeds.

CEO Statement

“Our users have lost the ability to make choices due to neurological disorders. Generative AI can offer predictions that are contextual to your environment, and the BCI enables individual choices to be made,” said Tom Oxley, CEO & founder of Synchron. “BCIs preserve and extend a fundamental human right: the freedom of expression. We take our autonomy for granted until it is gone. This is a pivotal moment at the convergence of powerful technologies that can restore lives.”

Manufacturing and Technical Details

Synchron manufactures its Stentrode implant using a thin-film process, which prints layers of nitinol and insulation contacts serving as electrodes. Chief Technology Officer Riki Banerjee explained that the company’s recent acquisition of an equity stake in thin-film component maker Acquandas supports this manufacturing process.

Endovascular Delivery Method

Synchron's endovascular delivery method aims to make BCI technology simpler and safer, offering more accessibility than invasive open-brain surgery. The company has garnered significant support, raising an oversubscribed $75 million Series C financing round in 2022, with participation from Gates Frontier and Bezos Expeditions.

Clinical Trials and Regulatory Milestones

In September 2023, Synchron completed enrollment for its COMMAND clinical trial and achieved the first FDA investigational device exemption for a permanently implanted BCI. The company is striving to beat Neuralink to FDA approval and commercialization, as Neuralink continues its own in-human trial and recently announced plans for a second human implant.